Table 1.
Development of CIA and antibody responses to CII
Arthritis | Onset (day | Anti-CII IgG (μ g/ml | ||||
(frequency of | max score of | in serum 35 days | ||||
Sex | Mice | CIA) | arthritic mice) | Severity | after immunization) | |
Male | Lm | Sham | 11/11 | 25 ± 4 | 8.4 ± 1.5 | 182 ± 73 |
Tx | 9/9 | 33 ± 9 | 9.1 ± 2.0 | 328 ± 206 | ||
MMC | Sham | 2/8 | 34 ± 6 | 4.5 ± 5.0 | 63 ± 112 | |
Tx | 3/8 | 56 ± 22 | 2.0 ± 1.0 | 40 ± 49 | ||
Female | Lm | Sham | 6/7 | 35 ± 15 | 7.2 ± 2.8 | 614 ± 413 |
Tx | 7/8 | 43 ± 16 | 7.6 ± 3.0 | 423 ± 273 | ||
MMC | Sham | 0/8 | - | - | 30 ± 25 | |
Tx | 2/10 | 64 ± 1.4 | 3.0 ± 2.8 | 24 ± 33 |
lm, nontransgenic littermates; Sham, sham-operated; Tx, thymectomized. Where applicable, values are expressed as mean ± standard deviation.